AU2018230521B2 - Pharmaceutical compositions and uses thereof - Google Patents

Pharmaceutical compositions and uses thereof Download PDF

Info

Publication number
AU2018230521B2
AU2018230521B2 AU2018230521A AU2018230521A AU2018230521B2 AU 2018230521 B2 AU2018230521 B2 AU 2018230521B2 AU 2018230521 A AU2018230521 A AU 2018230521A AU 2018230521 A AU2018230521 A AU 2018230521A AU 2018230521 B2 AU2018230521 B2 AU 2018230521B2
Authority
AU
Australia
Prior art keywords
metyrapone
oxazepam
equal
less
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018230521A
Other languages
English (en)
Other versions
AU2018230521A1 (en
Inventor
Kripanath Borah
Jay BREAUX
Muralikrishna Duvvuri
Carol GLOFF
Bruce Rehlaender
Julie Straub
Winston A. Vadino
Parag M. Ved
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Embera Neurotherapeutics Inc
Original Assignee
Embera Neurotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Embera Neurotherapeutics Inc filed Critical Embera Neurotherapeutics Inc
Publication of AU2018230521A1 publication Critical patent/AU2018230521A1/en
Application granted granted Critical
Publication of AU2018230521B2 publication Critical patent/AU2018230521B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2018230521A 2017-03-10 2018-03-12 Pharmaceutical compositions and uses thereof Ceased AU2018230521B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469798P 2017-03-10 2017-03-10
US62/469,798 2017-03-10
PCT/US2018/021939 WO2018165649A1 (en) 2017-03-10 2018-03-12 Pharmaceutical compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2018230521A1 AU2018230521A1 (en) 2019-10-17
AU2018230521B2 true AU2018230521B2 (en) 2022-02-03

Family

ID=63449154

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018230521A Ceased AU2018230521B2 (en) 2017-03-10 2018-03-12 Pharmaceutical compositions and uses thereof

Country Status (9)

Country Link
US (1) US11179377B2 (enExample)
EP (1) EP3592350B1 (enExample)
JP (1) JP7048629B2 (enExample)
CN (1) CN110582278B (enExample)
AU (1) AU2018230521B2 (enExample)
BR (1) BR112019018700A2 (enExample)
CA (1) CA3055940A1 (enExample)
EA (1) EA201992142A1 (enExample)
WO (1) WO2018165649A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022015160A (es) * 2020-06-02 2023-01-16 Scherer Technologies Llc R P Capsulas de gelatina blanda de liberacion retardada.
CN119606886B (zh) * 2025-01-09 2025-10-17 成都苑东生物制药股份有限公司 一种奥沙西泮的药物组合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160346261A1 (en) * 2005-11-10 2016-12-01 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
WO2016209929A1 (en) * 2015-06-22 2016-12-29 Embera Neurotherapeutics, Inc Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
US20170051007A1 (en) * 2015-08-03 2017-02-23 Pop Test Oncology Limited Liability Company Pharmaceutical compositions and methods

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3264450D1 (en) * 1981-12-11 1985-08-01 Wyeth John & Brother Ltd Process and apparatus for freezing a liquid medium
US4942162A (en) 1982-03-31 1990-07-17 University Of Tennessee Research Corporation Topical treatment of seborrheic dermatitis with ketoconazole
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4594329A (en) 1984-05-14 1986-06-10 The Salk Institute For Biological Studies CRF analogs
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4661493A (en) 1985-03-29 1987-04-28 Pfizer Inc. Tioconazole and related compounds for control of Herpes simplex virus
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5016655A (en) 1986-10-21 1991-05-21 C.A. Blockers, Inc. Cigarette manufacturing process
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US4925844A (en) 1988-02-09 1990-05-15 Ici Americas Inc. Antagonizing the pharmacological effects of a benzodiazepine receptor agonist
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE3842007A1 (de) 1988-12-14 1990-06-21 Henkel Kgaa Fluessiges bis pastoeses, bleichmittelhaltiges waschmittel
US4974729A (en) 1989-04-17 1990-12-04 Bristol-Myers Squibb Company Reminder system for taking medication
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5008528A (en) 1989-07-14 1991-04-16 Logitech S.A. Invertible trackball
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
JPH06506105A (ja) 1990-08-29 1994-07-14 ファーミング　ビーブイ 哺乳動物細胞における相同性組換え
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6323312B1 (en) 1994-12-12 2001-11-27 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
US6326463B1 (en) 1994-12-12 2001-12-04 The Salk Institute For Biological Studies Cyclic CRF agonists
US20030211157A1 (en) 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5869474A (en) 1997-05-16 1999-02-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage treatment for cocaine craving and withdrawal
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
NZ334627A (en) 1999-03-12 2002-07-26 Horticulture & Food Res Inst A therapeutic composition containing a therapeutic agent such as an anthelmintic and an antistress agent such as metyrapone or a nitric oxide promoter for increasing efficacy of therapeutic agents and animal growth
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US6630449B2 (en) 2000-12-21 2003-10-07 David Wastchak Method for reducing the effect of nicotine addiction and dependancy
AU2002322475B2 (en) 2001-06-26 2008-02-21 North Carolina State University Blocking peptide for inflammatory cell secretion
GB0205253D0 (en) 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
EP2011489A3 (en) 2002-07-09 2009-04-22 Roberta Gottlieb Method to inhibit ischemia and reperfusion injury
KR100503889B1 (ko) 2002-07-20 2005-07-26 한국과학기술연구원 옥틸로늄 브로마이드를 함유하는 항암제 흡수 증진제
MXPA05000294A (es) 2002-07-30 2005-08-19 Peter Migaly Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040067986A1 (en) 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
US20050037983A1 (en) 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
US20040185170A1 (en) 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
US20080206138A1 (en) 2003-08-06 2008-08-28 Ilse Zolle Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives
BRPI0414238A (pt) 2003-09-09 2006-10-31 Ono Pharmaceutical Co antagonistas de crf e compostos heterobicìclicos
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
JPWO2005061508A1 (ja) 2003-12-22 2007-07-12 小野薬品工業株式会社 三環式複素環化合物およびその化合物を有効成分とする医薬
JP4399593B2 (ja) 2004-04-01 2010-01-20 国立大学法人 千葉大学 インフルエンザ脳症の検査法、及び、ヒト髄液中に発現するタンパク質からなるマーカ、診断薬、診断キット
CA2568159A1 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors
JP2008500998A (ja) 2004-05-28 2008-01-17 シュペーデル・エクスペリメンタ・アーゲー 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
CA2643802A1 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
JP5197569B2 (ja) 2006-03-29 2013-05-15 ノバルティス アーゲー 有機化合物
MX2009006631A (es) 2006-12-18 2009-06-30 Novartis Ag Imidazoles como inhibidores de sintasa de aldosterona.
WO2008079868A1 (en) 2006-12-22 2008-07-03 Drugtech Corporation Clonidine composition and method of use
WO2009035473A2 (en) 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
CA2761858A1 (en) 2009-05-15 2010-11-18 Novartis Ag 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
SG175925A1 (en) 2009-05-15 2011-12-29 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors
AU2010247391A1 (en) 2009-05-15 2011-12-01 Novartis Ag Benzoxazolone derivatives as aldosterone synthase inhibitors
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
WO2011061168A1 (en) 2009-11-17 2011-05-26 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
US8575160B2 (en) 2009-11-30 2013-11-05 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
HUE041967T2 (hu) 2010-01-14 2019-06-28 Novartis Ag Mellékvese hormon-módosító szer alkalmazása
KR20130135820A (ko) 2010-06-16 2013-12-11 엠베라 뉴로 테라퓨틱스 인코포레이티드 중독，정신 장애 및 신경퇴행성 질환 치료용 조성물 및 방법
US20120237482A1 (en) 2011-03-18 2012-09-20 Juan Rodriguez Methods for treatment of neurological disorders by modulation of microglial activation
US20150278438A1 (en) 2012-04-23 2015-10-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Genetic predictors of response to treatment with crhr1 antagonists
WO2014131825A1 (en) 2013-03-01 2014-09-04 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical formulations comprising quetiapine and escitalopram
EP3013342B1 (en) 2013-06-27 2021-04-14 Cedars-Sinai Medical Center Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN104288385A (zh) 2014-10-23 2015-01-21 朱道明 一种戒毒中药
US20200016134A1 (en) 2016-02-16 2020-01-16 Embera Neurotherapeutics, Inc. Compositions and methods for treating substance abuse disorders
US20190275058A1 (en) 2016-03-04 2019-09-12 Embera Neurotherapeutics, Inc. Compositions and methods for treating addiction or substance use disorders
US20200360400A1 (en) 2017-05-19 2020-11-19 Embera Neurotherapeutics, Inc. Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160346261A1 (en) * 2005-11-10 2016-12-01 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
WO2016209929A1 (en) * 2015-06-22 2016-12-29 Embera Neurotherapeutics, Inc Compositions and methods for the treatment of substance use disorders, addiction, and psychiatric disorders
US20170051007A1 (en) * 2015-08-03 2017-02-23 Pop Test Oncology Limited Liability Company Pharmaceutical compositions and methods

Also Published As

Publication number Publication date
CN110582278A (zh) 2019-12-17
US11179377B2 (en) 2021-11-23
BR112019018700A2 (pt) 2020-04-07
WO2018165649A1 (en) 2018-09-13
CN110582278B (zh) 2023-04-18
AU2018230521A1 (en) 2019-10-17
EP3592350A4 (en) 2020-12-23
EA201992142A1 (ru) 2020-04-07
JP2020511455A (ja) 2020-04-16
JP7048629B2 (ja) 2022-04-05
US20200054615A1 (en) 2020-02-20
EP3592350B1 (en) 2025-03-05
CA3055940A1 (en) 2018-09-13
EP3592350A1 (en) 2020-01-15

Similar Documents

Publication Publication Date Title
US20210322368A1 (en) Solid dosage form composition for buccal or sublingual administration of cannabinoids
EP1511481B1 (en) Ophthalmological use of roflumilast for the treatment of diseases of the eye
TWI522100B (zh) 含有納布啡（ｎａｌｂｕｐｈｉｎｅ）之藥學組成物及其用途
CN103502224A (zh) 氟马西尼络合物、包含该络合物的组合物及其用途
KR20130116164A (ko) 벤다무스틴의 경구 투약 형태 및 그것의 치료 용도
AU2018420535B2 (en) Edaravone pharmaceutical composition
CN104981246A (zh) 治疗瘙痒的方法
TW201247240A (en) Rapid dissolve tablet compositions for vaginal administration
US20180000792A1 (en) Modified release compositions of epalrestat or a derivative thereof and methods for using the same
AU2018230521B2 (en) Pharmaceutical compositions and uses thereof
HU225779B1 (en) Pharmaceutical composition containing paracetamol and drotaverine and process for producing it
US20130172381A1 (en) Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
CN118252833A (zh) Vofopitant用于治疗肺纤维化的用途
KR20090024248A (ko) Ｃｘｃｒ2의 선택적 길항제 또는 ｃｘｃｒ1과 ｃｘｃｒ2 둘다의 선택적 길항제의 약제학적 제형 및 조성물, 및 염증성 질환을 치료하기 위한 이의 사용방법
WO2010038240A9 (en) Pharmaceutical composition comprising nimesulide and levocetirizine
US11858908B2 (en) Compositions and methods for inhibiting IDO1
EA042299B1 (ru) Фармацевтические композиции и их применения
WO2012075744A1 (zh) 含有吡唑并嘧啶酮样化合物的药物组合物
WO2005016315A1 (en) Pharmaceutical compositions of nateglinide and a high amount of a water-soluble filler
KR20250075160A (ko) 항히스타민제 및 류코트리엔 길항제를 약리 활성 물질으로 함유하는 위체류 이중층 복합 제제
US20240082176A1 (en) Dropropizine in combination with ambroxol in the dosage form of syrup and tablets
HK1226662A1 (en) Modified release compositions of epalrestat or a derivative thereof and methods for using the same
HK1191569B (en) Modified release compositions of epalrestat or a derivative thereof and methods for using the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired